NZ617350B2 - Pyrazole derivatives and their use for the treatment of diseases relating to TAARs, such as depression, psychosis, Parkinson's disease, ADHD and diabetes - Google Patents
Pyrazole derivatives and their use for the treatment of diseases relating to TAARs, such as depression, psychosis, Parkinson's disease, ADHD and diabetes Download PDFInfo
- Publication number
- NZ617350B2 NZ617350B2 NZ617350A NZ61735012A NZ617350B2 NZ 617350 B2 NZ617350 B2 NZ 617350B2 NZ 617350 A NZ617350 A NZ 617350A NZ 61735012 A NZ61735012 A NZ 61735012A NZ 617350 B2 NZ617350 B2 NZ 617350B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- morpholinyl
- pyrazolecarboxamide
- disorders
- halogen
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims description 34
- 206010061536 Parkinson's disease Diseases 0.000 title claims description 12
- 206010061920 Psychotic disease Diseases 0.000 title claims description 10
- 206010012601 Diabetes mellitus Diseases 0.000 title claims description 9
- 102000011829 Trace amine associated receptor family Human genes 0.000 title abstract description 21
- 108050002178 Trace amine associated receptor family Proteins 0.000 title abstract description 21
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 title description 6
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 title description 5
- 150000003217 pyrazoles Chemical class 0.000 title description 2
- -1 pyrazole derivative compounds Chemical class 0.000 claims abstract description 146
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 208000008466 Metabolic Disease Diseases 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical group 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 24
- 238000007792 addition Methods 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 9
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 9
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010057666 Anxiety disease Diseases 0.000 claims description 7
- 206010027599 Migraine Diseases 0.000 claims description 7
- 208000008085 Migraine Disorders Diseases 0.000 claims description 7
- 235000014632 disordered eating Nutrition 0.000 claims description 7
- 201000006180 eating disease Diseases 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 201000009032 substance abuse Diseases 0.000 claims description 7
- 231100000736 substance abuse Toxicity 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 5
- 206010004938 Bipolar disease Diseases 0.000 claims description 5
- 208000002249 Diabetes Complications Diseases 0.000 claims description 5
- 206010012655 Diabetic complications Diseases 0.000 claims description 5
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 5
- 206010015037 Epilepsy Diseases 0.000 claims description 5
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 5
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 230000036760 body temperature Effects 0.000 claims description 5
- 230000027288 circadian rhythm Effects 0.000 claims description 5
- 230000035591 circadian rhythms Effects 0.000 claims description 5
- 238000005265 energy consumption Methods 0.000 claims description 5
- 230000013632 homeostatic process Effects 0.000 claims description 5
- 230000000926 neurological Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 230000007958 sleep Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 4
- 206010012378 Depression Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 4
- 230000001225 therapeutic Effects 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 230000000271 cardiovascular Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 80
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 208000009025 Nervous System Disease Diseases 0.000 abstract 2
- 206010029305 Neurological disorder Diseases 0.000 abstract 2
- 230000000051 modifying Effects 0.000 abstract 2
- LDTMDAXTIIYCCP-XFULWGLBSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-1-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.FC(F)(F)C1=NC=CC(N2N=C(C=C2)C(=O)NC=2C=CC(=CC=2)[C@@H]2OCCNC2)=N1 LDTMDAXTIIYCCP-XFULWGLBSA-N 0.000 abstract 1
- CDBAUVASGKOPMQ-FSRHSHDFSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-3-phenyl-1H-pyrazole-5-carboxamide;hydrochloride Chemical compound Cl.C1=C(C=2C=CC=CC=2)NN=C1C(=O)NC(C=C1)=CC=C1[C@H]1CNCCO1 CDBAUVASGKOPMQ-FSRHSHDFSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 91
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 210000003702 immature single positive T cell Anatomy 0.000 description 75
- 239000000203 mixture Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- XEKPKIIGRGWXNX-UHFFFAOYSA-N C1(=CC=CC=C1)C1(NNC=C1)C(=O)O Chemical compound C1(=CC=CC=C1)C1(NNC=C1)C(=O)O XEKPKIIGRGWXNX-UHFFFAOYSA-N 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- 235000019341 magnesium sulphate Nutrition 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 20
- 229940093499 ethyl acetate Drugs 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- 230000027455 binding Effects 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- RYLFTAZSKDUPAA-CYBMUJFWSA-N tert-butyl (2S)-2-(4-aminophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C1=CC=C(N)C=C1 RYLFTAZSKDUPAA-CYBMUJFWSA-N 0.000 description 15
- 101710015409 SLC7A5 Proteins 0.000 description 14
- 102100002432 TAAR1 Human genes 0.000 description 14
- 229960004132 diethyl ether Drugs 0.000 description 14
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- RYLFTAZSKDUPAA-ZDUSSCGKSA-N tert-butyl (2R)-2-(4-aminophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@@H]1C1=CC=C(N)C=C1 RYLFTAZSKDUPAA-ZDUSSCGKSA-N 0.000 description 11
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000010640 amide synthesis reaction Methods 0.000 description 10
- 210000004027 cells Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 230000037261 ClH Effects 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002287 radioligand Substances 0.000 description 8
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 8
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1H-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 7
- MLCNOCRGSBCAGH-UHFFFAOYSA-N 2,3-dichloropyrazine Chemical compound ClC1=NC=CN=C1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- QBPUOAJBMXXBNU-UHFFFAOYSA-N 3-phenyl-1H-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=CC=CC=2)=N1 QBPUOAJBMXXBNU-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000001184 potassium carbonate Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- FZRBTBCCMVNZBD-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(Cl)=N1 FZRBTBCCMVNZBD-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000000035 biogenic Effects 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000008079 hexane Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000003169 Central Nervous System Anatomy 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 102000003688 G-protein coupled receptors Human genes 0.000 description 4
- 108090000045 G-protein coupled receptors Proteins 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- GSLFYQYBXIVNLS-UHFFFAOYSA-N 1-(3-bromo-2-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1F GSLFYQYBXIVNLS-UHFFFAOYSA-N 0.000 description 3
- BMAFEVVYEWGVTD-UHFFFAOYSA-N 3-(3-cyanophenyl)-1H-pyrazole-5-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1C1=CC=CC(C#N)=C1 BMAFEVVYEWGVTD-UHFFFAOYSA-N 0.000 description 3
- VNSXKSKOUFZMJH-UHFFFAOYSA-N 3-[3-(difluoromethoxy)phenyl]-1H-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=C(OC(F)F)C=CC=2)=N1 VNSXKSKOUFZMJH-UHFFFAOYSA-N 0.000 description 3
- AVVLVCYNVBXDSH-UHFFFAOYSA-N 4-[(4,6-dimethoxy-1,3,5-triazin-2-yl)methyl]morpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC(C[NH+]2CCOCC2)=N1 AVVLVCYNVBXDSH-UHFFFAOYSA-N 0.000 description 3
- 102000017910 Adrenergic receptor family Human genes 0.000 description 3
- 108060003345 Adrenergic receptor family Proteins 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- 229940113083 morpholine Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- UUIDDBRUOCXTAO-ZDUSSCGKSA-N tert-butyl (2R)-2-(4-bromophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@@H]1C1=CC=C(Br)C=C1 UUIDDBRUOCXTAO-ZDUSSCGKSA-N 0.000 description 3
- UUIDDBRUOCXTAO-CYBMUJFWSA-N tert-butyl (2S)-2-(4-bromophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C1=CC=C(Br)C=C1 UUIDDBRUOCXTAO-CYBMUJFWSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- OYGSDSZQKGMLJZ-UHFFFAOYSA-N 1-(4-fluorophenyl)pyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=C(F)C=C1 OYGSDSZQKGMLJZ-UHFFFAOYSA-N 0.000 description 2
- JJXFXQHRMKSBAO-UHFFFAOYSA-N 1-[4-(difluoromethoxy)phenyl]pyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=C(OC(F)F)C=C1 JJXFXQHRMKSBAO-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N 2-Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- KNFQNIDFVSYISO-UHFFFAOYSA-N 3-(5-cyano-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1C1=CC(C#N)=CC=C1F KNFQNIDFVSYISO-UHFFFAOYSA-N 0.000 description 2
- OVEGSCLVOXWLIV-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=CC(Cl)=N1 OVEGSCLVOXWLIV-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940045348 Brown mixture Drugs 0.000 description 2
- 238000006418 Brown reaction Methods 0.000 description 2
- NKJDKADPKAUPGC-GHXNOFRVSA-N CCOC(=O)C(\O)=C\C(=O)C1=CC=C(C#N)C=C1 Chemical compound CCOC(=O)C(\O)=C\C(=O)C1=CC=C(C#N)C=C1 NKJDKADPKAUPGC-GHXNOFRVSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 230000036947 Dissociation constant Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 206010027603 Migraine headache Diseases 0.000 description 2
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- KGLXMJNATGVJDD-UHFFFAOYSA-N methyl 3-[3-(difluoromethoxy)phenyl]-1H-pyrazole-5-carboxylate Chemical compound N1C(C(=O)OC)=CC(C=2C=C(OC(F)F)C=CC=2)=N1 KGLXMJNATGVJDD-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- RBZSNYRIYQEKKA-VWLOTQADSA-N tert-butyl (2R)-2-[4-(benzhydrylideneamino)phenyl]morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@@H]1C1=CC=C(N=C(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 RBZSNYRIYQEKKA-VWLOTQADSA-N 0.000 description 2
- RBZSNYRIYQEKKA-RUZDIDTESA-N tert-butyl (2S)-2-[4-(benzhydrylideneamino)phenyl]morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C1=CC=C(N=C(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 RBZSNYRIYQEKKA-RUZDIDTESA-N 0.000 description 2
- XRMJVBFFOONDPK-JOCHJYFZSA-N tert-butyl (2S)-2-[4-[(3-phenyl-1H-pyrazole-5-carbonyl)amino]phenyl]morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C(C=C1)=CC=C1NC(=O)C1=NNC(C=2C=CC=CC=2)=C1 XRMJVBFFOONDPK-JOCHJYFZSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- CSRAZBQUAVXIOL-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-2-yl]pyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=C(C(F)(F)F)C=N1 CSRAZBQUAVXIOL-UHFFFAOYSA-N 0.000 description 1
- LAWUBNJMRGMNQD-UHFFFAOYSA-N 1-phenylpyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=CC=C1 LAWUBNJMRGMNQD-UHFFFAOYSA-N 0.000 description 1
- JVSDZAGCHKCSGR-UHFFFAOYSA-N 2,5-dichloropyrazine Chemical compound ClC1=CN=C(Cl)C=N1 JVSDZAGCHKCSGR-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- NZIVEAHQMHZMNU-UHFFFAOYSA-N 2-(4-methylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1N1C(C(O)=O)=CC=N1 NZIVEAHQMHZMNU-UHFFFAOYSA-N 0.000 description 1
- OFGSIPQYQUVVPL-UHFFFAOYSA-N 2-bromo-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CN=C1Br OFGSIPQYQUVVPL-UHFFFAOYSA-N 0.000 description 1
- GOHBBINNYAWQGO-UHFFFAOYSA-N 2-bromo-3-chloropyridine Chemical compound ClC1=CC=CN=C1Br GOHBBINNYAWQGO-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- RTLPJOKBLILHNK-UHFFFAOYSA-N 2-iodo-3-(trifluoromethyl)pyrazine Chemical compound FC(F)(F)C1=NC=CN=C1I RTLPJOKBLILHNK-UHFFFAOYSA-N 0.000 description 1
- JGDJDKQYABTXBQ-UHFFFAOYSA-N 3-(2-methoxyphenyl)-1H-pyrazole-5-carboxylic acid Chemical compound COC1=CC=CC=C1C1=NNC(C(O)=O)=C1 JGDJDKQYABTXBQ-UHFFFAOYSA-N 0.000 description 1
- XJZLQBGNAQXXGE-UHFFFAOYSA-N 3-(3-chlorophenyl)-1H-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=C(Cl)C=CC=2)=N1 XJZLQBGNAQXXGE-UHFFFAOYSA-N 0.000 description 1
- IEQRHIQFNLEJMF-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1H-pyrazole-5-carboxylic acid Chemical compound COC1=CC=CC(C2=NNC(=C2)C(O)=O)=C1 IEQRHIQFNLEJMF-UHFFFAOYSA-N 0.000 description 1
- VHWPBROOEIJLIW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-1H-pyrazole-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=NNC(C(O)=O)=C1 VHWPBROOEIJLIW-UHFFFAOYSA-N 0.000 description 1
- RQNDMQXNIOALFA-UHFFFAOYSA-N 3-propanoylbenzonitrile Chemical compound CCC(=O)C1=CC=CC(C#N)=C1 RQNDMQXNIOALFA-UHFFFAOYSA-N 0.000 description 1
- OFXNHFCCZGMNQE-UHFFFAOYSA-N 4-(difluoromethoxy)benzenediazonium;tetrafluoroborate Chemical compound F[B-](F)(F)F.FC(F)OC1=CC=C([N+]#N)C=C1 OFXNHFCCZGMNQE-UHFFFAOYSA-N 0.000 description 1
- NLPHXWGWBKZSJC-UHFFFAOYSA-N 4-acetylbenzonitrile Chemical compound CC(=O)C1=CC=C(C#N)C=C1 NLPHXWGWBKZSJC-UHFFFAOYSA-N 0.000 description 1
- BEWDZECYRLIWRS-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-1H-pyrazole-3-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1CC1=CC=C(F)C=C1 BEWDZECYRLIWRS-UHFFFAOYSA-N 0.000 description 1
- ZPBNABIKZKTQQH-UHFFFAOYSA-N 5-bromopyrazine-2-carbonitrile Chemical compound BrC1=CN=C(C#N)C=N1 ZPBNABIKZKTQQH-UHFFFAOYSA-N 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- XLWHFWXEBYEOCR-POHAHGRESA-N COC(=O)C(\O)=C\C(=O)C1=CC=CC(OC(F)F)=C1 Chemical compound COC(=O)C(\O)=C\C(=O)C1=CC=CC(OC(F)F)=C1 XLWHFWXEBYEOCR-POHAHGRESA-N 0.000 description 1
- 229960001701 Chloroform Drugs 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N Norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- 229960001576 Octopamine Drugs 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 206010037175 Psychiatric disease Diseases 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100007632 TAAR2 Human genes 0.000 description 1
- 101700014494 TAAR2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000030014 alpha-1 adrenergic receptor family Human genes 0.000 description 1
- 102000019633 alpha-2 adrenergic receptor family Human genes 0.000 description 1
- 108020004101 alpha-2 adrenergic receptor family Proteins 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- KDFQYGBJUYYWDJ-UHFFFAOYSA-N azane;sodium Chemical compound N.[Na] KDFQYGBJUYYWDJ-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ACONPURZGJUVLW-UHFFFAOYSA-N chloroform;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl ACONPURZGJUVLW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- HMIDGNCOOWAJAI-UHFFFAOYSA-N ethyl 1-[4-(difluoromethoxy)phenyl]pyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=CN1C1=CC=C(OC(F)F)C=C1 HMIDGNCOOWAJAI-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- MVFGXYPEQHIKIX-UHFFFAOYSA-M heptane;acetate Chemical compound CC([O-])=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- BHYIWNVAMBROFT-MRXNPFEDSA-N tert-butyl (2S)-2-[4-(1H-pyrazole-5-carbonylamino)phenyl]morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C(C=C1)=CC=C1NC(=O)C1=NNC=C1 BHYIWNVAMBROFT-MRXNPFEDSA-N 0.000 description 1
- QUBNPUPUCMVUFI-UHFFFAOYSA-N tert-butyl 3-(4-aminophenyl)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1C1=CC=C(N)C=C1 QUBNPUPUCMVUFI-UHFFFAOYSA-N 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-O tetrafluoroboric acid Chemical compound [H+].F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-O 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Provided are pyrazole derivative compounds of general formula IA or IB, wherein the variables are as defined in the specification. Examples of the compounds include (S)-N-(4-(morpholin-2-yl)phenyl)-5-phenyl-1H -pyrazole-3-carboxamide hydrochloride and (S)-N-(4-(Morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazole-3-carboxamide hydrochloride. The compounds are modulators of trace amine associated receptors (TAARs). The compounds may be useful in the treatment of metabolic or neurological disorders. methyl)pyrimidin-4-yl)-1H-pyrazole-3-carboxamide hydrochloride. The compounds are modulators of trace amine associated receptors (TAARs). The compounds may be useful in the treatment of metabolic or neurological disorders.
Description
PYRAZOLE DERIVATIVES AND THEIR USE FOR TREATMENT OF DISEASES
RELATING TO TAARs, SUCH AS DEPRESSION, PSYCHOSIS, PARKINSON'S
DISEASE, ADHD AND DIABETES
Pop/21.03.2012
The invention relates to compounds of formula
R
1
N
N
N
H
O
NH
Z
R
2
R
3
IA or
R
1
N
N
N
H
O
NH
Z
R
2
R
4
IB
wherein
R
1
is hydrogen or phenyl, optionally substituted by halogen, CN or lower alkoxy or lower
alkoxy substituted by halogen;
R
2
is hydrogen or lower alkyl;
R
3
is hydrogen or lower alkyl or is
phenyl substituted by one or more substituents, selected from halogen, cyano or lower
alkoxy substituted by halogen, or is
pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is
pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is
pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen;
R
4
is hydrogen, lower alkyl or phenyl;
Z is a bond, -CH2- or –O-;
or to a pharmaceutically suitable acid addition salt thereof.
The invention includes all racemic mixtures, all their corresponding enantiomers and/or optical
isomers. In addition, all tautomeric forms of compounds of formula IA and IB are also
encompassed by the present invention.
It has now been found that the compounds of formulas IA and IB have a good
affinity to the trace amine associated receptors (TAARs), especially for TAAR1.
The compounds may be used for the treatment of depression, anxiety disorders, bipolar
disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders,
psychotic disorders such as schizophrenia, neurological diseases such as Parkinson’s
disease, neurodegenerative disorders such as Alzheimer’s disease, epilepsy, migraine,
hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes,
diabetic complications, obesity, dyslipidemia, disorders of energy consumption and
assimilation, disorders and malfunction of body temperature homeostasis, disorders of
sleep and circadian rhythm, and cardiovascular disorders.
Some of the physiological effects (i.e. cardiovascular effects, hypotension, induction of
sedation) which have been reported for compounds which may bind to adrenergic receptors
(WO02/076950, WO97/12874 or EP 0717 037) may be considered to be undesirable side effects
in the case of medicaments aimed at treating diseases of the central nervous system as described
above. Therefore it is desirable to obtain medicaments having selectivity for the TAAR1 receptor
vs adrenergic receptors. Objects of the present invention show selectivity for TAAR1 receptor
over adrenergic receptors, in particular good selectivity vs the human and rat alpha1 and alpha2
adrenergic receptors.
The classical biogenic amines (serotonin, norepinephrine, epinephrine, dopamine,
histamine) play important roles as neurotransmitters in the central and peripheral nervous system
[1]. Their synthesis and storage, as well as their degradation and reuptake after release are tightly
regulated. An imbalance in the levels of biogenic amines is known to be responsible for the
altered brain function under many pathological conditions [2-5]. A second class of endogenous
amine compounds, the so-called trace amines (TAs) significantly overlaps with the classical
biogenic amines regarding structure, metabolism and subcellular localization. The TAs include
p-tyramine, β-phenylethylamine, tryptamine and octopamine, and they are present in the
mammalian nervous system at generally lower levels than classical biogenic amines [6].
Their dysregulation has been linked to various psychiatric diseases like schizophrenia and
depression [7] and for other conditions like attention deficit hyperactivity disorder, migraine
headache, Parkinson’s disease, substance abuse and eating disorders [8,9].
For a long time, TA-specific receptors had only been hypothesized based on
anatomically discrete high-affinity TA binding sites in the CNS of humans and other
mammals [10,11]. Accordingly, the pharmacological effects of TAs were believed to be
mediated through the well known machinery of classical biogenic amines, by either
triggering their release, inhibiting their reuptake or by “crossreacting” with their receptor
systems [9,12,13]. This view changed significantly with the recent identification of
several members of a novel family of GPCRs, the trace amine associated receptors
(TAARs) [7,14]. There are 9 TAAR genes in human (including 3 pseudogenes) and 16
genes in mouse (including 1 pseudogene). The TAAR genes do not contain introns (with
one exception, TAAR2 contains 1 intron) and are located next to each other on the same
chromosomal segment. The phylogenetic relationship of the receptor genes, in
agreement with an in-depth GPCR pharmacophore similarity comparison and
pharmacological data suggest that these receptors form three distinct subfamilies [7,14].
TAAR1 is in the first subclass of four genes (TAAR1-4) highly conserved between
human and rodents. TAs activate TAAR1 via Gαs. Dysregulation of TAs was shown to
contribute to the aetiology of various diseases like depression, psychosis, attention
deficit hyperactivity disorder, substance abuse, Parkinson’s disease, migraine headache,
eating disorders, metabolic disorders and therefore TAAR1 ligands have a high potential
for the treatment of these diseases.
Therefore, there is a broad interest to increase the knowledge about trace amine associated
receptors.
References used:
1 Deutch, A.Y. and Roth, R.H. (1999) Neurotransmitters. In Fundamental Neuroscience (2nd
edn) (Zigmond, M.J., Bloom, F.E., Landis, S.C., Roberts, J.L, and Squire, L.R., eds.), pp.
193-234, Academic Press;
2 Wong, M.L. and Licinio, J. (2001) Research and treatment approaches to depression. Nat.
Rev. Neurosci. 2, 343-351;
3 Carlsson, A. et al. (2001) Interactions between monoamines, glutamate, and GABA in
schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260;
4 Tuite, P. and Riss, J. (2003) Recent developments in the pharmacological treatment of
Parkinson's disease. Expert Opin. Investig. Drugs 12, 1335-1352,
Castellanos, F.X. and Tannock, R. (2002) Neuroscience of attention-deficit/hyperactivity
disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3, 617-628;
6 Usdin, Earl; Sandler, Merton; Editors. Psychopharmacology Series, Vol. 1: Trace Amines
and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American
College of Neuropsychoparmacology, San Juan, Puerto Rico] (1976);
7 Lindemann, L. and Hoener, M. (2005) A renaissance in trace amines inspired by a novel
GPCR family. Trends in Pharmacol. Sci. 26, 274-281;
8 Branchek, T.A. and Blackburn, T.P. (2003) Trace amine receptors as targets for novel
therapeutics: legend, myth and fact. Curr. Opin. Pharmacol. 3, 90-97;
9 Premont, R.T. et al. (2001) Following the trace of elusive amines. Proc. Natl. Acad. Sci. U.
S. A. 98, 9474-9475;
10 Mousseau, D.D. and Butterworth, R.F. (1995) A high-affinity [3H] tryptamine binding site
in human brain. Prog. Brain Res. 106, 285-291;
11 McCormack, J.K. et al. (1986) Autoradiographic localization of tryptamine binding sites in
the rat and dog central nervous system. J. Neurosci. 6, 94-101;
12 Dyck, L.E. (1989) Release of some endogenous trace amines from rat striatal slices in the
presence and absence of a monoamine oxidase inhibitor. Life Sci. 44, 1149-1156;
13 Parker, E.M. and Cubeddu, L.X. (1988) Comparative effects of amphetamine,
phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol
binding. J. Pharmacol. Exp. Ther. 245, 199-210;
14 Lindemann, L. et al. (2005) Trace amine associated receptors form structurally and
functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85,
372-385.
Aspects of the present invention are new compounds of formula IA and IB and their
pharmaceutically acceptable salts, their use for the manufacture of medicaments for the treatment
of diseases related to the biological function of the trace amine associated receptors, their
manufacture and medicaments based on a compound in accordance with the invention in the
control or prevention of illnesses such as depression, anxiety disorders, bipolar disorder,
attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as
schizophrenia, neurological diseases such as Parkinson’s disease, neurodegenerative disorders
such as Alzheimer’s disease, epilepsy, migraine, substance abuse and metabolic disorders such
as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy
consumption and assimilation, disorders and malfunction of body temperature homeostasis,
disorders of sleep and circadian rhythm, and cardiovascular disorders.
The preferred indications using the compounds of the present invention are depression,
psychosis, Parkinson’s disease, anxiety and attention deficit hyperactivity disorder (ADHD) and
diabetes.
As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain
group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-
butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon
atoms.
As used herein, the term "lower alkoxy" denotes a group wherein the alkyl residue is as
defined above and which is attached via an oxygen atom.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
As used herein, the term "lower alkoxy substituted by halogen" denotes an alkoxy group
as defined above and wherein at least one hydrogen atom is replaced by halogen.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic
and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric
acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
One embodiment of the invention are compounds of formula IA-1
(R)n
N
N
N
H
O
NH
R
2
R
3
Z
IA-1
wherein
R is hydrogen, halogen, CN or lower alkoxy or lower alkoxy substituted by halogen;
R
2
is hydrogen or lower alkyl;
R
3
is hydrogen or lower alkyl;
Z is a bond, -CH2- or –O-;
n is 1 or 2; if n = 2, each R may be defined independently of the other;
or a pharmaceutically suitable acid addition salt thereof, for example the following compounds:
or a pharmaceutically suitable acid addition salt thereof, for example the following compounds:
(S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
(S)(3-cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(5-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or
(S)(3-(difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide.
One further embodiment of the invention are compounds of formula IB-1
(R)n
N
N
N
H
O
NH
R
2
R
4
Z
IB-1
wherein
R is hydrogen, halogen, CN or lower alkoxy or lower alkoxy substituted by halogen;
R
2
is hydrogen or lower alkyl;
R
4
is hydrogen or lower alkyl;
Z is a bond, -CH2- or –O-;
n is 1 or 2; if n = 2, each R may be defined independently of the other;
or a pharmaceutically suitable acid addition salt thereof, for example the following compounds:
(S)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
(S)(4-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(2-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(2-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3,4-dimethoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-chlorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
(S)(4-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(4-fluorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-methoxyphenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(4-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide
(R)(3-cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide
(rac) 3-(3-cyanophenyl)-N-(4-(pyrrolidinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-(difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide
(S)(3-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or
(S)(3-(difluoromethoxy)phenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide.
One embodiment of the invention are compounds of formula IA-2,
R
1
N
N
N
H
O
NH
R
2
R
3
Z
IA-2
R
1
is hydrogen
R
2
is hydrogen or lower alkyl;
R
3
phenyl substituted by one or more substituents, selected from halogen, cyano or lower
alkoxy substituted by halogen, or is
pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is
pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is
pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen;
Z is a bond, -CH2- or –O-;
or a pharmaceutically suitable acid addition salt thereof, for example the following compounds:
(S)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(5-chloropyridinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole
carboxamide
(S)(4-cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole
carboxamide
(S)(4-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(R)(4-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide
(S)(6-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(3-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)(5-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
(S)-N-(4-(morpholinyl)phenyl)(6-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide
(S)-N-(4-(morpholinyl)phenyl)(6-(trifluoromethyl)pyrazinyl)-1H-pyrazole
carboxamide
(S)(5-cyanopyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or
(S)-N-(4-(morpholinyl)phenyl)(2-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide.
One further embodiment of the invention are compounds of formula IB-2,
N
N
N
H
O
NH
R
2
R
4
Z
R
1
IB-2
wherein
R
1
is hydrogen
R
2
is hydrogen or lower alkyl;
R
4
is hydrogen, lower alkyl or phenyl
Z is a bond, -CH2- or –O-;
or a pharmaceutically suitable acid addition salt thereof, for example the following compound
(S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide.
The present compounds of formula IA and IB and their pharmaceutically acceptable salts
can be prepared by methods known in the art, for example, by processes described below, which
process comprises
a) cleaving off the N-protecting group from compounds of formula
R
1
N
N
N
H
O
N
Z
R
2
R
3
PG
4-A or
R
1
N
N
N
H
O
N
Z
R
2
R
4
PG
4-B
to a compound of formula
R
1
N
N
N
H
O
NH
Z
R
2
R
3
IA or
R
1
N
N
N
H
O
NH
Z
R
2
R
4
IB
wherein PG is a N-protecting group selected from –C(O)O-tert-butyl and the other definitions
are as described above, and,
if desired, converting the compounds obtained into pharmaceutically acceptable acid
addition salts.
The preparation of compounds of formula IA and IB of the present invention may be
carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the
invention are shown in the following schemes 1 to 3 and in the description of 54 specific
examples. The skills required for carrying out the reactions and purification of the resulting
products are known to those skilled in the art. The substituents and indices used in the following
description of the processes have the significance given herein before unless indicated to the
contrary.
In more detail, the compounds of formula IA and IB can be manufactured by the methods
given below, by the methods given in the examples or by analogous methods. Appropriate
reaction conditions for the individual reaction steps are known to a person skilled in the art. The
reaction sequence is not limited to the one displayed in schemes 1 to 3, however, depending on
the starting materials and their respective reactivity the sequence of reaction steps can be freely
altered. Starting materials are either commercially available or can be prepared by methods
analogous to the methods given below, by methods described in references cited in the
description or in the examples, or by methods known in the art.
GENERAL PROCEDURE
Scheme 1
2NH
N
Z
O O
H2N
N
O
O O
2NH
N
O O
2NH
N
O
O
R
1
N
N
R
2
R
3
Cl
O
R
1
N
N
R
2
R
3
O
N
H
N
Z O
O
R
1
N
N
R
2
R
3
O
N
H
NH Z
R
1
N
N
R
2
R
3
OH
O
2
A
Amide formation A
Amide formation
3-A-2
4-A
IA
B
Cleavage of
protecting group
For examples using
2-a 2-b
2-c
3-A-1
The substituents are as described above.
Step A: Amide formation can be accomplished by a coupling reaction between an amine 2
and acid chloride compounds 3-A-2 in halogenated solvents such as dichloromethane or 1,2-
dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF, DME or TBME, in the
presence of an organic base such as triethylamine or N,N-diisopropylethylamine. Examples of
appropriate amines 2 include N-protected morpholine derivatives such as 2-a [CAS 1002726
6], piperidine derivatives such as 2-b [CAS 8757981], pyrrolidine derivatives such as 2-c
[CAS 9083341].
Preferred conditions are triethylamine in THF at room temperature for 18 hours.
Alternatively, amide formation can be accomplished by a coupling reaction between an amine 2
and carboxylic acids 3-A-1 in the presence of a coupling reagent such as DCC, EDC, TBTU,
HBTU or HATU in the presence of an organic base such as triethylamine, N,Ndiisopropylethylamine or N-methylmorpholine in halogenated solvents such as DMF,
dichloromethane or 1,2-dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF,
DME or TBME.
Preferred conditions are HBTU with N-methylmorpholine in DMF at 60 °C for 18 hours.
Step B: Removal of the BOC N-protecting group can be effected with mineral acids such as HCl,
H2SO4 or H3PO4 or organic acids such as CF3COOH, CHCl2COOH, HOAc or p-toluenesulfonic
acid in solvents such as CH2Cl2, CHCl3, THF, Dioxane, MeOH, EtOH or H2O at 0 to 80 °C.
Preferred conditions are HCl in dioxane at 60 °C for 1-20 h.
Scheme 2
2NH
N
Z
O O
H2N
N
O
O O
2NH
N
O O
2NH
N
O
O
R
1
N
N
OH
O
R
2
R
4
R
1
N
N
R
2
O
N
H
N
Z O
O
R
4
N
N
Cl
O
R
2
R
4
R
1
R
1
N
N
R
2
O
N
H
NH Z
R
4
2
A
Amide formation A
Amide formation
3-B-2
4-B
IB
B
Cleavage of
protecting group
For examples using
2-a 2-b
2-c
3-B-1
The process conditions are the same as described for scheme 1.
Scheme 3
2NH
N
Z
O O
R
3
O
N
N
X
R
2
O
NH
N
OH
R
2
O
N
H
N
Z O
O
NH
N
R
2
R
3 Y
R
3
O
N
H
N
Z O
O
N
N
R
2
R
3
O
N
H
NH Z
N
N
R
2
2
C
Amide formation
4-A-2
IA-2
D
Cleavage of
protecting group
+
A
Amide formation
+
6
B
CN-Bond
Formation
8a X=Cl
8b X= OH
+
7
wherein
Y is halogen, R2 is hydrogen or lower alkyl; R3 is phenyl optionally substituted by one or more
substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl,
optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl,
optionally substituted by lower alkyl substituted by halogen, or is pyrazinyl, optionally
substituted by halogen, cyano or lower alkyl substituted by halogen; and Z is a bond, -CH2- or
–O-;
Step A: Formation of amide 6 can be accomplished by a coupling reaction between an amine 2
and 1H-pyrazolecarboxylic acid 5 using a selective coupling reagent such as 4-(4,6-
dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride in a solvent such as methanol,
ethanol or isopropanol at temperatures of 0°C to 50°C for 1 h to 24 hrs.
Preferred conditions are the use of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium
chloride in methanol for 1 h at 0°C followed by 18 hours stirrung at room temperature.
Examples of appropriate amines 2 include N-protected morpholine derivatives such as 2-a [CAS
10027266], piperidine derivatives such as 2-b [CAS 8757981], pyrrolidine derivatives
such as 2-c [CAS 9083341].
Step B: C-N bond formation can be accomplished by treatment of aryl halide 7 or heteroaryl
halide 7 with pyrazole 6 in the presence of a palladium or copper catalyst, a ligand and a base in
solvents such as dioxane, DME, THF, toluene, DMF and DMSO at elevated temperatures, for
instance using a palladium-catalysed Buchwald-Hartwig reaction.
Preferred conditions are catalytic tris(dibenzylidineacetone)dipalladium chloroform complex,
catalytic 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (xantphos) and caesium carbonate in
dioxane in a sealed tube heated at 100 °C overnight according to a modification of the procedure
of van Leeuwen and co-workers (Tetrahedron. Lett. 1999, 40, 3789-3790).
In case the aryl halide 7 or heteroaryl halide 7 is activated towards undergoing nucleophilic
substitution due to the presence of electron withdrawing substitutuents, preferably by the
presence of a trifluoromethylgroup, coupling with the pyrazole 6 can be achieved by reacting
these compounds in the presence of a base such as diisopropylethylamine, triethylamine,
potassium carbonate or sodium hydride in a solvent such as isopropanol, dioxane,
dimethylsulfoxide, dimethylacetamide or dimethylformamide at a temperature between 50 °C
and 140°C for 1 hour to 24 hours.
Preferred conditions are heating the mixture of 6 and 7 with potassium carbonate in
dimethylacetamide at 120 °C for 20 hours.
Step C: Amide formation can be accomplished by a coupling reaction between an amine 2
and acid chloride compounds 8a in halogenated solvents such as dichloromethane or 1,2-
dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF, DME or TBME, in the
presence of an organic base such as triethylamine or N,N-diisopropylethylamine.
Preferred conditions are triethylamine in THF at room temperature for 18 hours.
Alternatively, amide formation can be accomplished by a coupling reaction between an amine 2
and carboxylic acids 8b in the presence of a coupling reagent such as DCC, EDC, TBTU, HBTU
or HATU in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine
or N-methylmorpholine in halogenated solvents such as DMF, dichloromethane or 1,2-
dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF, DME or TBME.
Preferred conditions are HBTU with N-methylmorpholine in DMF at 60 °C for 18 hours.
Step D: Removal of the BOC N-protecting group can be effected with mineral acids such as HCl,
H2SO4 or H3PO4 or organic acids such as CF3COOH, CHCl2COOH, HOAc or p-toluenesulfonic
acid in solvents such as CH2Cl2, CHCl3, THF, Dioxane, MeOH, EtOH or H2O at 0 to 80 °C.
Preferred conditions are HCl in dioxane at 60 °C for 1-20 h.
The same general process as described in scheme 3 may be used for the preparation of
compounds of formula IB-2.
Isolation and purification of the compounds
Isolation and purification of the compounds and intermediates described herein can be
effected, if desired, by any suitable separation or purification procedure such as, for example,
filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thicklayer chromatography, preparative low or high-pressure liquid chromatography or a combination
of these procedures. Specific illustrations of suitable separation and isolation procedures can be
had by reference to the preparations and examples herein below. However, other equivalent
separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral
compounds of formula I can be separated using chiral HPLC.
Salts of compounds of formula IA and IB
The compounds of formula IA and IB are basic and may be converted to a corresponding acid
addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount
of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid,
pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid,
tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid,
ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is
dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or
methanol and the like, and the acid added in a similar solvent. The temperature is maintained
between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of
solution with a less polar solvent.
The acid addition salts of the basic compounds of formula IA and IB may be converted to
the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable
base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate,
ammonia, and the like.
Example 1
(S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide hydrochloride
N
H
N
N
H
O
N
H
O
a) (S)-tert-butyl 2-(4-(5-phenyl-1H-pyrazolecarboxamido)phenyl)morpholine
carboxylate
In a 25 mL round-bottomed flask, (S)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate
(100 mg, 359 µmol, Eq: 1.00), 3-phenyl-1H-pyrazolecarboxylic acid (87.9 mg, 467 µmol,
Eq: 1.3) (CAS49-2), N-Methylmorpholine (109 mg, 118 µl, 1.08 mmol, Eq: 3) and
HBTU (204 mg, 539 µmol, Eq: 1.5) were combined with DMF (3.75 ml). The reaction
mixture was stirred at 60°C for 16.5 hours. The mixture was poured into water (10ml) and
extracted twice with EtOAc. The organic layers were washed with brine, dried over MgSO4
,
filtered and concentrated in vacuo. The crude material was purified by column
chromatography. (6 g silica gel (63-200A), eluent: heptane/EtOAc 2:1) to give the title
compound as a white solid (120 mg, 74.5%). MS (ISP): 449.5 ([M+H]+
).
b) (S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide hydrochloride
To a solution of (S)-tert-butyl 2-(4-(5-phenyl-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (120 mg, 268 µmol, Eq: 1.00) in dioxane
(0.5 ml) was added 4M-HCl in dioxane (1.00 ml, 4.01 mmol, Eq: 15). The reaction mixture
was stirred at 60°C for 2h. To the mixture was then added 10 ml of dioxane and the
suspension was filtered off, washed with ether and dried under in high vacuum to give the
target compound as a white solid (82.3 mg, 79.9%). MS (ISP): 349.2 ([M+H]+
).
Preparation of (S)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate:
Step a) (S)(4-Bromophenyl)morpholine:
2.27 g (RS)(4-Bromo-phenyl)-morpholine (CAS82-0) were separated on a
Chiralpak IA (8x32 cm) using n-Heptane/ethanol (1:11) + 0.1% DEA.
(S)(4-Bromo-phenyl)-morpholine: collected from 7.6 min to 9.4 min.
Yield 0.97g (42.9%) with 97.4% ee
(R)(4-Bromo-phenyl)-morpholine: collected from 9.8 min to 13.9 min
Yield 0.99g (43.6%) with 97.4% ee
Step b) (S)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate
(S)(4-Bromo-phenyl)-morpholine (36.3 g, 150 mmol) and N,N-diisopropylethylamine
(23.3 g, 31.4 ml, 180 mmol) in THF (360 ml) were treated with di-tert-butyl dicarbonate
(39.3 g, 180 mmol). The reaction mixture was stirred for 17 h at rt, concentrated in vacuo,
diluted with ethyl acetate, washed with 1M-citric acid (2x100 ml), dried over magnesium
sulfate, filtered and concentrated in vacuo. The crude material was crystallized from hexane
to afford 47.1 g (92%) (S)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate as a offwhite solid. MS (ISP): 344.1 ([M+H]+
).
Step c) (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholinecarboxylate:
(S)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate (47 g, 137 mmol),
diphenylmethanimine (29.9 g, 27.6 m, 165 mmol), BINAP (6.41 g, 10.3 mmol) and
Pd2(dba)3 (3.14 g, 3.43 mmol) were dissolved under Argon in dry and de-aerated toluene
(940 ml) and treated with sodium tert-butoxide (18.5 g, 192 mmol). The dark brown mixture
was stirred at 90°C for 18 h. The yellow/brown reaction mixture was diluted with toluene
(700 ml), cooled to rt and extracted twice with water. The organic layer was separated, dried
over magnesium sulfate and concentrated in vacuo. The crude product was diluted with 300
ml hexane, stirred for 1 h and filtered off, leading to an orange solid (68 g) which was
purified by column chromatography (1.3 Kg silicagel, 20% ethylacetate/heptane). The
combined and concentrated fractions were suspended in hexane, stirred for 17 h, filtered off
andf dried in high vacuo, to yield 54.1 g (89%) yellow solid. MS (ISP): 443.3 ([M+H]+
).
Step d) (S)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate
A suspension of (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine
carboxylate (54.1 g, 122 mmol), ammonium formate (116 g, 1.83 mol) and Pd/C 5% (6.5 g,
3.06 mmol) in methanol (930 ml) was stirred at 60°C for 2 h. The reaction mixture was
filtered and concentrated. The residue was dissolved in ethyl acetate and water. The organic
phase was extracted twice with 0.5M HCl. The combined aqueous phases were basified with
2M-NaOH and extracted twice with DCM. The organic phases were dried over magnesium
sulfate, filtered and dried in vacuo, to yield 31.95 g off-white solid. MS (ISP): 279.1
([M+H]+
).
Example 2
(S)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using 5-(3-chloro-phenyl)-1Hpyrazolecarboxylic acid (CAS50-7) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 383.12 ([M+H]+
).
Example 3
(S)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
F
The title compound was prepared in analogy to Example 1 using 5-(4-fluoro-phenyl)-1H20 pyrazolecarboxylic acid (CAS22-6) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 367.15 ([M+H]+
).
Example 4
(S)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
O
The title compound was prepared in analogy to Example 1 using 5-(3-methoxy-phenyl)-1Hpyrazolecarboxylic acid (CAS54-1) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 379.17 ([M+H]+
).
Example 5
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
The title compound was prepared in analogy to Example 1 using 1-Methylphenyl-1Hpyrazolecarboxylic acid (CAS64-3) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 363.18 ([M+H]+
).
Example 6
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
The title compound was prepared in analogy to Example 1 using 4-Methylphenyl-2Hpyrazolecarboxylic acid (CAS33-9) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
Off-white solid. MS (ISP): 363.5 ([M+H]+
).
Example 7
(S)(4-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
O
The title compound was prepared in analogy to Example 1 using 5-(4-methoxy-phenyl)-2Hpyrazolecarboxylic acid (CAS- 270695) instead of 5-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 379.4 ([M+H]+
).
Example 8
(S)(2-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
F
The title compound was prepared in analogy to Example 1 using 5-(2-fluoro-phenyl)-2H15 pyrazolecarboxylic acid (CAS87-6) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 367.1 ([M+H]+
).
Example 9
(S)(2-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
O
The title compound was prepared in analogy to Example 1 using 5-(2-methoxy-phenyl)-2Hpyrazolecarboxylic acid (CAS- 8348681) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 379.4 ([M+H]+
).
Example 10
(S)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using 3-(2-chlorophenyl)-1Hpyrazolecarboxylic acid (CAS13-3) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 383.2 ([M+H]+
).
Example 11
(S)(3,4-dimethoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
O
O
The title compound was prepared in analogy to Example 1 using 5-(3,4-dimethoxy-phenyl)-2H20 pyrazolecarboxylic acid (CAS88-1) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
Off-white solid. MS (ISP): 409.3 ([M+H]+
).
Example 12
(R)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate instead of (S)-tert-butyl 2-(4-aminophenyl)morpholine4-carboxylate and 3-(4-chlorophenyl)-1H-pyrazolecarboxylic acid (CAS63-2) instead
of 3-phenyl-1H-pyrazolecarboxylic acid.
Off-white solid. MS (ISP): 383.1 ([M+H]+
).
Preparation of (R)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate:
Step a) (R)(4-Bromophenyl)morpholine:
2.27 g (RS)(4-Bromo-phenyl)-morpholine (CAS82-0) were separated on a
Chiralpak IA (8x32 cm) using n-Heptane/ethanol (1:11) + 0.1% DEA.
(S)(4-Bromo-phenyl)-morpholine: collected from 7.6 min to 9.4 min.
Yield 0.97g (42.9%) with 97.4% ee
(R)(4-Bromo-phenyl)-morpholine: collected from 9.8 min to 13.9 min
Yield 0.99g (43.6%) with 97.4% ee
Step b) (R)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate:
(R)(4-Bromophenyl)morpholine (6 g, 24.8 mmol) and N,N-diisopropylethylamine (3.84 g,
.19 ml, 29.7 mmol) in THF (60 ml) were treated with di-tert-butyl dicarbonate (6.49 g,
29.7mmol). The reaction mixture was stirred for 17 h at rt, concentrated in vacuo, diluted with
ethyl acetate, washed with 1M-citric acid, dried over magnesium sulfate, filtered and
concentrated in vacuo. The crude material was crystallized from heptane/ethyl acetate to afford
8.48 g (87%) (R)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate as a white solid. MS
(ISP): 344.1 ([M+H]+
).
Step c) (R)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholinecarboxylate:
(R)-tert-butyl 2-(4-bromophenyl)morpholinecarboxylate (5.4 g, 15.8 mmol),
diphenylmethanimine (3.43 g, 3.17 ml, 18.9 mmol), BINAP (737 mg, 1.18 mmol) and Pd2(dba)3
(361 mg, 0.39 mmol) were dissolved under Argon in dry and de-aerated toluene (108 ml) and
treated with sodium tert-butoxide (2.12 g, 22.1 mmol). The dark brown mixture was stirred at
90°C for 18 h. The yellow/brown reaction mixture was diluted with toluene (100 ml), cooled to
rt and extracted twice with water. The organic layer was separated, dried over magnesium sulfate
and concentrated in vacuo. The crude product was diluted with 50 ml hexane, stirred for 1 h and
filtered off, leading to a yellow solid (7.4 g) which was purified by column chromatography (50
g silicagel, 5% to 15% ethylacetate/heptane). The combined and concentrated fractions were
suspended in hexane, stirred for 17 h, filtered off andf dried in high vacuo, to yield 6.15 g (86%)
yellow solid. MS (ISP): 443.4 ([M+H]+
).
Step d) (R)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate:
A suspension of (R)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholinecarboxylate
(6 g, 13.6 mmol), ammonium formate (12.8 g, 203 mmol) and Pd/C 5% (721 mg, 0.339 mmol)
in methanol (103 ml) was stirred at 60°C for 2 h. The reaction mixture was filtered and
concentrated. The residue was dissolved in ethyl acetate and water. The organic phase was
extracted twice with 0.5M HCl. The combined aqueous phases were basified with 2M-NaOH
and extracted twice with DCM. The organic phases were dried over magnesium sulfate, filtered
and dried in vacuo, to yield 3.04 g off-white solid. MS (ISP): 279.1 ([M+H]+
).
Example 13
(R)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate (prepared in Example 12) instead of (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate and 3-(2-chlorophenyl)-1H-pyrazolecarboxylic acid
(CAS13-3) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Light brown solid. MS (ISP): 383.1 ([M+H]+
).
Example 14
(S)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using 3-(4-chlorophenyl)-1Hpyrazolecarboxylic acid (CAS63-2) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
Off-white solid. MS (ISP): 383.1 ([M+H]+
).
Example 15
(R)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
Cl 10
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate (prepared in Example 12) instead of (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate and 3-(3-chlorophenyl)-1H-pyrazolecarboxylic acid
(CAS50-7) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 383.1 ([M+H]+
).
Example 16
(R)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
NH
N
H
O
N
H
O
O
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate (prepared in Example 12) instead of (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate and 3-(3-methoxyphenyl)-1H-pyrazolecarboxylic
acid (CAS64-7) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 379.2 ([M+H]+
).
Example 17
(S)(3-chlorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
Cl
The title compound was prepared in analogy to Example 1 using 5-(3-Chloro-phenyl)methyl10 2H-pyrazolecarboxylic acid (CAS32-7) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 397.1 ([M+H]+
).
Example 18
(S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
The title compound was prepared in analogy to Example 1 using 1-Methylphenyl-1Hpyrazolecarboxylic acid (CAS53-8) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
Off-white solid. MS (ISP): 363.2 ([M+H]+
).
Example 19
(R)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate (prepared in Example 12) instead of (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate and 1-Methylphenyl-1H-pyrazolecarboxylic acid
(CAS64-3) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 363.3 ([M+H]+
).
Example 20
(S)(3-cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
NC
The title compound was prepared in analogy to Example 1 using 5-(3-Cyano-phenyl)-1Hpyrazolecarboxylic acid (CAS10-6) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
Light brown solid. MS (ISP): 374.0 ([M+H]+
).
Example 21
(S)(4-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
NC 20
The title compound was prepared in analogy to Example 1 using 3-(4-cyanophenyl)methyl1H-pyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Light brown solid. MS (ISP): 388.0 ([M+H]+
).
Preparation of 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylic acid:
Step a) (Z)-ethyl 4-(4-cyanophenyl)hydroxyoxobutenoate:
In a dry flask, under argon atmosphere, sodium (317 mg, 13.8 mmol, Eq: 1.00) was added
portionwise to ethanol (9.0 ml). (The temperature increased to 60°C). The reaction mixture was
cooled at 0°C. Then Diethyl oxalate (2.01 g, 1.87 ml, 13.8 mmol, Eq: 1.00) was added dropwise
followed by 4-acetylbenzonitrile (2 g, 13.8 mmol, Eq: 1.00) in Ethanol (3.00 ml). A white solid
appeared. The reaction was stirred with mechanical stirrer overnight and monitored by TLC.
Then the reaction mixture was concentrated in vacuo. The residue was cooled at 0°C and water
was added to the flask. 1M HCl was added to this solution (pH=3), then the solution was
extracted two times with EtOAc. The organic layer was washed three times with 20mL Brine.
The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo to give an
off-white solid. This off-white solid was mixed with Ether at 0°C. The suspension was filtered to
give a white solid (2.082 g, 61.6%).
Step b) Ethyl 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylate:
Under argon atmosphere (Z)-ethyl 4-(4-cyanophenyl)hydroxyoxobutenoate (500mg,
2.04 mmol, Eq: 1.00) was dissolved in Ethanol (10 ml) at rt.. Methylhydrazine (95.9 mg, 110 µl,
2.04 mmol, Eq: 1.00) was added dropwise (The solution became yellow). The solution was
stirred overnight at rt followed by 6h heating at 50°C, cooled down to rt and concentrated.in
vacuo. The residue was directly purified by column chromatography (20g) Heptane/EtOAC: 9/1
to give the expected pyrazole (173 mg, 33.2%) as a white solid.
MS (ISP): 256.3 ([M+H]+
).
Step c) 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylic acid:
To a solution of ethyl 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylate (70 mg, 274 µmol,
Eq: 1.00) in THF (5 ml) and MeOH (1.00 ml) was added LiOH 1M (548 µl, 548 µmol, Eq: 2).
The mixture was stirred for ca. 8h at rt., then treated with water and HCl 1N (pH:3). The mixture
was extracted two times with ethyl acetate. The resulting organic layers were combined, washed
with Brine and dried over MgSO4, filtered and concentrated to give the desired compound
(55mg, 88.3%) as a white solid.
MS (ISP): 228.2 (M+1).
Example 22
(S)(4-fluorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
F
The title compound was prepared in analogy to Example 1 using 5-(4-Fluoro-phenyl)methyl1H-pyrazolecarboxylic acid (CAS70-5) instead of 3-phenyl-1H-pyrazole
carboxylic acid.
Light brown solid. MS (ISP): 381.1 ([M+H]+
).
Example 23
(S)(3-methoxyphenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
O
The title compound was prepared in analogy to Example 1 using 5-(3-Methoxy-phenyl)
methyl-1H-pyrazolecarboxylic acid (CAS47-8) instead of 3-phenyl-1H-pyrazole
carboxylic acid.
Light brown solid. MS (ISP): 381.1 ([M+H]+
).
Example 24
(S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
CN
The title compound was prepared in analogy to Example 1 using 3-(3-cyanophenyl)methyl1H-pyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Light brown solid. MS (ISP): 388.0 ([M+H]+
).
Preparation of 3-(3-cyanophenyl)methyl-1H-pyrazolecarboxylic acid:
In analogy to 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylic acid, described in Example
21.
Example 25
(S)(3-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
CN
The title compound was prepared in analogy to Example 1 using 3-(3-cyanophenyl)ethyl-1Hpyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Off-white solid. MS (ISP): 402.1 ([M+H]+
).
Preparation of 3-(3-cyanophenyl)ethyl-1H-pyrazolecarboxylic acid:
In analogy to 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylic acid, described in Example
21.
Example 26
(S)(4-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
NC
The title compound was prepared in analogy to Example 1 using 3-(4-cyanophenyl)ethyl-1Hpyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Off-white solid. MS (ISP): 402.1 ([M+H]+
).
Preparation of 3-(4-cyanophenyl)ethyl-1H-pyrazolecarboxylic acid:
In analogy to 3-(4-cyanophenyl)methyl-1H-pyrazolecarboxylic acid, described in Example
21.
Example 27
(S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
CN
The title compound was prepared in analogy to Example 1 using 5-(3-cyanophenyl)methyl1H-pyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Brown solid. MS (ISP): 388.1 ([M+H]+
).
Preparation of 5-(3-cyanophenyl)methyl-1H-pyrazolecarboxylic acid:
Step a) lithium (Z)(3-cyanophenyl)ethoxymethyl-1,4-dioxobutenolate:
To a magnetically stirred solution of LiHMDS in THF 1M (7.94 ml, 7.94 mmol, Eq: 1.00) in
Et2O (50 ml) at -78°C was added dropwise a solution of 3-propionylbenzonitrile (1.264 g, 7.94
mmol, Eq: 1.00) in Et2O (10.0 ml) under argon atmosphere. After the mixture was stirred at the
same temperature for an additional period of 45 min, diethyl oxalate (1.22 g, 1.13 ml, 8.34 mmol,
Eq: 1.05) was added dropwise. The reaction mixture was allowed to warm to rt and stirred for 3
days. The precipitate formed was collected by filtration, washed with diethyl ether, and dried
under vacuum to afford the desired lithium salt as a yellow solid (929 mg, 44.1%).
Step b) Ethyl 5-(3-cyanophenyl)methyl-1H-pyrazolecarboxylate:
To a solution of lithium (Z)(3-cyanophenyl)ethoxymethyl-1,4-dioxobutenolate
(400 mg, 1.51 mmol, Eq: 1.00) in Ethanol (10 ml) was added Hydrazine hydrochloride (113 mg,
1.65 mmol, Eq: 1.093) at rt to give an orange solution. The resulting mixture was stirred
overnight at the same temperature. After 1 day the solvent was removed under reduce pressure
and to the mixture was added brine. The solution was extracted two times with AcOEt, and the
combined organic layers were dried over MgSO4, filtered and concentrated to give the desired
compound as a yellow gum (114mg, 26.6%).
MS (ISP): 256.0 ([M+H]+
).
Step c) 3-(3-cyanophenyl)methyl-1H-pyrazolecarboxylic acid:
To a solution of ethyl 5-(3-cyanophenyl)methyl-1H-pyrazolecarboxylate (100 mg, 392
µmol, Eq: 1.00) in THF (5 ml) in MeOH (1.00 ml) was added LiOH 1M (2.35 ml, 2.35 mmol,
Eq: 6). The mixture was stirred overnight. To the residue was added water and HCl 1N (pH:1),
this aqueous phase was extracted two times with ethyl acetate, the resulting organic layers were
combined and washed with brine, dried over MgSO4, filtered and concentrated in vacuo to
afford the desired compound (52mg, 52.6%) as a yellow solid.
MS (ISP): 228.1 (M+1).
Example 28
(S)(5-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
N
H
O
N
H
O
CN
F
The title compound was prepared in analogy to Example 1 using 5-(5-cyanofluorophenyl)-
1H-pyrazolecarboxylic acid instead of 3-phenyl-1H-pyrazolecarboxylic acid.
Brown solid. MS (ISP): 392.0 ([M+H]+
).
Preparation of 5-(5-cyanofluorophenyl)-1H-pyrazolecarboxylic acid:
In analogy to 5-(3-cyanophenyl)methyl-1H-pyrazolecarboxylic acid, described in Example
21.
Example 29
(S)(4-Fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
F
The title compound was prepared in analogy to Example 1 using 1-(4-fluorophenyl)-1Hpyrazolecarboxylic acid (CAS34-6) in THF instead of 3-phenyl-1H-pyrazole
carboxylic acid in DMF.
White solid. MS (ISP): 367.0 ([M+H]+
).
Example 30
(S)-N-(4-(Morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide hydrochloride
N
N
N
H
O
N
H
O
The title compound was prepared in analogy to Example 1 using 1-phenyl-1H-pyrazole
carboxylic acid (CAS77-3) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 349.1 ([M+H]+
).
Example 31
(R)(4-Fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
F
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate instead of (S)-tert-butyl 2-(4-aminophenyl)morpholine4-carboxylate and 1-(4-fluorophenyl)-1H-pyrazolecarboxylic acid (CAS34-6)
instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 367.0 ([M+H]+
).
Example 32
(S)(5-Chloropyridinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
N
Cl
The title compound was obtained in analogy to example 47 using 2-bromochloropyridine
instead of 2-chloro(trifluoromethyl)pyrimidine in step b).
Off-white solid. MS (ISP): 384.2 ([M+H]+
).
Example 33
(S)-N-(4-(Morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
N
CF3
The title compound was obtained in analogy to example 47 using 2-bromo
(trifluoromethyl)pyridine instead of 2-chloro(trifluoromethyl)pyrimidine in step b).
White solid. MS (ISP): 418.2 ([M+H]+
).
Example 34
(S)(4-Cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
N
H
O
N
H
O
CN
The title compound was obtained in analogy to example 47 using 2-bromo-benzonitrile instead
of 2-chloro(trifluoromethyl)pyrimidine in step b).
Off-white solid. MS (ISP): 374.3 ([M+H]+
).
Example 35
(R)-N-(4-(Morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
N
CF3
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate instead of (S)-tert-butyl 2-(4-aminophenyl)morpholine4-carboxylate and 1-(5-Trifluoromethyl-pyridinyl)-1H-pyrazolecarboxylic acid (CAS10069626) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 418.2 ([M+H]+
).
Example 36
(S)(3-Cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
H
N
H
O
N
H
CN
The title compound was prepared in analogy to Example 1 using 5-(3-Cyano-phenyl)-1H20 pyrazolecarboxylic acid (CAS10-6) instead of 3-phenyl-1H-pyrazolecarboxylic
acid.
White solid. MS (ISP): 372.0 ([M+H]+
).
Example 37
(R)(3-Cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
H
N
H
O
N
H
CN
The title compound was prepared in analogy to Example 1 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate instead of (S)-tert-butyl 2-(4-aminophenyl)morpholine4-carboxylate and 5-(3-Cyano-phenyl)-1H-pyrazolecarboxylic acid (CAS10-6)
instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 372.0 ([M+H]+
).
Example 38
(rac) 3-(3-Cyanophenyl)-N-(4-(pyrrolidinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
H
N
H
O
CN
NH
The title compound was prepared in analogy to Example 1 using 3-(4-Amino-phenyl)-
pyrrolidinecarboxylic acid tert-butyl ester (CAS28-1) instead of (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate and 5-(3-Cyano-phenyl)-1H-pyrazolecarboxylic acid
(CAS10-6) instead of 3-phenyl-1H-pyrazolecarboxylic acid.
White solid. MS (ISP): 357.8 ([M+H]+
).
Example 39
(S)(3-Cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
H
N
H
O
N
H
O
CN
F
The title compound was prepared in analogy to Example 1 using 5-(3-Cyanofluoro-phenyl)-
1H-pyrazolecarboxylic acid (prepared as indicated below: a-d) instead of 3-phenyl-1Hpyrazolecarboxylic acid.
White solid. MS (ISP): 392.1 ([M+H]+
).
Preparation of 5-(3-Cyanofluoro-phenyl)-1H-pyrazolecarboxylic acid:
a) Lithium (Z)(3-bromofluorophenyl)ethoxy-1,4-dioxobutenolate: to a
magnetically stirred solution of LiHMDS in THF 1M (9.22 ml, 9.22 mmol, Eq: 1) was
added Et2O (31.2 ml) at -78°C to give a yellow solution. To this mixture was added a
solution of 1-(3-bromofluorophenyl)ethanone (2 g, 9.22 mmol, Eq: 1.00) in Et2O
(15.6 ml) dropwise under argon atmosphere. The mixture was then stirred at the same
temperature for an additional period of 45 min. Diethyl oxalate (1.41 g, 1.31 ml, 9.68
mmol, Eq: 1.05) was then added dropwise. The reaction mixture was allowed to warm to
rt and stirred for another 2 days. The precipitate formed was collected by filtration,
washed with diethyl ether, and dried under vacuum to afford the desired lithium salt as a
light-yellow solid (2.677g, 89.9%).
b) Ethyl 5-(3-bromofluorophenyl)-1H-pyrazolecarboxylate: To a solution of lithium
(Z)(3-bromofluorophenyl)ethoxy-1,4-dioxobutenolate (600 mg, 1.86
mmol, Eq: 1.00) in Ethanol (25 ml) was added Hydrazine monohydrate (139 mg, 2.03
mmol, Eq: 1.093) at rt to give a white suspension, after 1h the suspension became a
solution. The resulting mixture was stirred overnight. After 1 day the reaction was
complete After stirring the solvent was removed under reduce pressure and to the mixture
was added brine, the solution was extracted two times with AcOEt, and the combined
organic layers were dried over Na2SO4, filtered and concentrated to give ethyl 5-(3-
bromofluorophenyl)-1H-pyrazolecarboxylate as a white solid (460 mg, 79.1%). MS
(ISP): 314.8 ([M+H]+
).
c) Ethyl 5-(3-cyanofluorophenyl)-1H-pyrazolecarboxylate: A mixture of ethyl 5-(3-
bromofluorophenyl)-1H-pyrazolecarboxylate (300 mg, 958 µmol, Eq: 1.00), Zinc
Cyanide (65.2 mg, 556 µmol, Eq: 0.58) and Pd(PPh3)4 (111 mg, 95.8 µmol, Eq: 0.1) was
heated at 160°C in DMF (2 ml) (stored over molecular sieves) for 30mins in microwave.
The mixture was partitioned between EtOAc (40 mL) and 2N NH4OH (40 mL). The
organic phase was extracted with 2N NH4OH, washed with Brine, dried over MgSO4
and concentrated in vacuo. The crude mixture was purified by column chromatography
(10g) eluent: Heptane/EtOAc : 95/5 to give the desired nitrile compound as a white
crystalline solid (180 mg, 72.5%). MS (ISP): 260.0 ([M+H]+
).
d) 5-(3-cyanofluorophenyl)-1H-pyrazolecarboxylic acid: To a solution of ethyl 5-(3-
cyanofluorophenyl)-1H-pyrazolecarboxylate (180 mg, 694 µmol, Eq: 1.00) in THF
(5.00 ml) and MeOH (1 ml) was added LiOH 1M (4.17 ml, 4.17 mmol, Eq: 6). The
mixture was stirred overnight. After addition of LiOH the solution was become orange.
To the residue was added water and HCl 1N (pH: 1), this aqueous phase was extracted
two times with ethyl acetate; the resulting organic layers were combined and washed with
Brine. Then dried over MgSO4, filtered and concentrated to give the desired compound
(45 mg, 22.4%) as a white solid. MS (ISP): 232.4 ([M+H]+
).
Example 40
(S)(3-(Difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
H
N
H
O
N
H
O
O
F F 25
The title compound was prepared in analogy to Example 1 using 5-(3-Difluoromethoxy-phenyl)-
2H-pyrazolecarboxylic acid (prepared as indicated below: a-c) instead of 3-phenyl-1Hpyrazolecarboxylic acid.
White solid. MS (ISP): 415.2 ([M+H]+
).
Preparation of 5-(3-Difluoromethoxy-phenyl)-2H-pyrazolecarboxylic acid:
a) 5-(3-Difluoromethoxy-phenyl)-2H-pyrazolecarboxylic acid methyl ester: To a solution
of (Z)-methyl 4-(3-(difluoromethoxy)phenyl)hydroxyoxobutenoate (CAS8327414) (800 mg, 2.94 mmol, Eq: 1.00) in Ethanol (20 ml) was added Hydrazine
hydrochloride (220 mg, 3.21 mmol, Eq: 1.093) at rt to give an orange suspension. The
resulting mixture was stirred overnight at the same temperature. After 1 day the reaction
was complete. After stirring the solvent was removed under reduce pressure and to the
mixture was added brine, the solution was extracted two times with AcOEt, and the
combined organic layers were dried over MgSO4, filtered and concentrated to give the
desired compound as a light-brown solid (630 mg, 79.9%). MS (ISP): 269.0 ([M+H]+
).
b) 5-(3-Difluoromethoxy-phenyl)-2H-pyrazolecarboxylic acid: To a solution of 5-(3-
Difluoromethoxy-phenyl)-2H-pyrazolecarboxylic acid methyl ester (620 mg, 2.31
mmol, Eq: 1.00) in THF (10 ml) and MeOH (2.00 ml) was added LiOH 1M (13.9 ml,
13.9 mmol, Eq: 6) to give a brown solution. The mixture was stirred overnight. After
addition of LiOH the solution was become. To the residue was added water and HCl 1N
(pH:1), this aqueous phase was extracted two times with ethyl acetate, the resulting
organic layers were combined and washed with Brine. Then dried over MgSO4, filtered
and concentrated to give the desired compound (510 mg, 86.8%) as a light-yellow solid.
MS (ISP): 255.0 ([M+H]+
).
Example 41
(S)(3-(Difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
O
F F
a) (S)-Tert-butyl 2-(4-(3-(3-(difluoromethoxy)phenyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate: In a 25 mL round-bottomed flask, 3-
(3-(difluoromethoxy)phenyl)-1H-pyrazolecarboxylic acid (515 mg, 2.03 mmol,
Eq: 1.1) (preparation described in example 40), (S)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate (513 mg, 1.84 mmol, Eq: 1.00) (preparation
described in example 1), N-Methylmorpholine (559 mg, 608 µl, 5.53 mmol, Eq: 3)
and HBTU (1.05 g, 2.76 mmol, Eq: 1.5) were combined with DMF (2 ml) to give a
yellow solution. The reaction mixture was stirred overnight at 60°C. The mixture was
poured into water (10ml) and extracted twice with EtOAc. The organic layers were
washed with NaHCO3, brine, dried over MgSO4
, filtered and concentrated in vacuo
to give a brown crude mixture. This mixture was diluted with Heptane, stirred for 15
minutes and the suspension was filtered. The resulting solid was washed several times
with Heptane to afford the desired compound as a brown solid (550mg, 58.0%).
b) (S)-Tert-butyl 2-(4-(5-(3-(difluoromethoxy)phenyl)ethyl-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate and (S)-tert-butyl 2-(4-(3-(3-
(difluoromethoxy)phenyl)ethyl-1H-pyrazolecarboxamido)phenyl)morpholine4-carboxylate:
To a mixture of (S)-tert-butyl 2-(4-(3-(3-(difluoromethoxy)phenyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (70 mg, 136 µmol, Eq: 1.00) and
potassium carbonate (41.4 mg, 299 µmol, Eq: 2.2) in DMF (2 ml) was added
iodoethane (25.5 mg, 13.2 µl, 163 µmol, Eq: 1.2) and stirred overnight at rt. To the
resulting mixture was added water and the organic phase was extracted with Water
and Brine, then the organic layer was dried over MgSO4, filtered off and
concentrated in vacuo to give the crude compound as a mixture of isomers which
were separated by column chromatography (10g-cartridge) to give: (S)-tert-butyl 2-
(4-(5-(3-(difluoromethoxy)phenyl)ethyl-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (17 mg, 23.0%) and (S)-tert-butyl 2-
(4-(3-(3-(difluoromethoxy)phenyl)ethyl-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (27mg, 36.6%).
c) (S)(3-(Difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1Hpyrazolecarboxamide hydrochloride: To a solution of (S)-tert-butyl 2-(4-(5-(3-
(difluoromethoxy)phenyl)ethyl-1H-pyrazolecarboxamido)phenyl)morpholine4-carboxylate (17 mg) in Dioxane (40.8 µl) was added 4M-HCl in dioxane (117 µl,
470 µmol, Eq: 15). The reaction mixture was stirred at 60°C overnight. To the
mixture was added 2ml of diethyl ether and stirred for 15 min at room temp. The
mixture was filtered and concentrated in high vacuum to give the expected
hydrochloride as a white solid (9 mg, 60.0%). MS (ISP): 443.1 ([M+H]+
).
Example 42
(S)(3-(Difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
O
F F
To a solution of (S)-tert-butyl 2-(4-(3-(3-(difluoromethoxy)phenyl)ethyl-1Hpyrazolecarboxamido)phenyl)morpholinecarboxylate (27mg) (prepared in
Example 41, b)) in Dioxane (40.8 µl) was added 4M-HCl in dioxane (117 µl, 470
µmol, Eq: 15). The reaction mixture was stirred at 60°C overnight. To the mixture
was added 2ml of diethyl ether and stirred for 15 min at room temp. The mixture was
filtered and concentrated in high vacuum to give the expected hydrochloride as a
white solid (15 mg, 63%). MS (ISP): 443.1 ([M+H]+
).
Example 43
(S)(3-Cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
N
H
N
H
O
N
H
O
CN
F
The title compound was prepared in analogy to Example 39 using 1-(3-bromo
fluorophenyl)ethanone instead of 1-(3-bromofluorophenyl)ethanone.
White solid. MS (ISP): 392.1 ([M+H]+
).
Example 44
(S)(3-(Difluoromethoxy)phenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
O
F F
The title compound was prepared in analogy to Example 42 using Methyl iodide instead of
Iodoethane.
White solid. MS (ISP): 429.1 ([M+H]+
).
Example 45
(S)(4-(Difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
N
N
H
O
N
H
O
O
F
F
a) Ethyl 2-chloro(2-(4-(difluoromethoxy)phenyl)hydrazono)acetate
4-(Difluoromethoxy)aniline (796 mg, 5 mmol) was dissolved in tetrafluoroboric acid (2.38 g, 1.7
ml, 13.0 mmol) and water (2 ml). After cooling to 0° C, a solution of sodium nitrite (345 mg,
.0 mmol) in water (0.75 ml) was slowly added. The mixture was stirred for 30 min and the
thick precipitate was collected by filtration and washed with diethylether (about 3 ml). The light
red solid was dissolved in 1.5 ml of acetone and 5 ml of diethylether was added. After stirring
for 15 min with cooling, the white solid was filtered, washed with diethylether and dried at HV
for 15 min to yield 4-difluoromethoxy-benzenediazonium tetrafluoroborate.
This diazonium salt (851 mg, 3.3 mmol) was added to a solution of ethyl 2-chloro
oxobutanoate (494 mg, 420 µl, 3 mmol) in pyridine (0.8 ml) and water (0.8 ml). The very thick
suspension was stirred at -5 ° C for 30 min. The solid was filtered, washed with ice cold water
and dried in vacuo to yield an orange solid (0.67 g, 76%). MS (ISP): 293.1 ([{35Cl}M+H]+
),
295.2 ([{37Cl}M+H]+
).
b) Ethyl 1-(4-(difluoromethoxy)phenyl)-1H-pyrazolecarboxylate
Ethyl 2-chloro(2-(4-(difluoromethoxy)phenyl)hydrazono)acetate (585 mg, 2 mmol) was
dissolved in toluene (4 ml) and 2,5-norbornadiene (906 mg, 1 ml, 9.83 mmol) and triethylamine
(587 mg, 808 µl, 5.8 mmol) were added. The reaction mixture was stirred at 70 ° C for 30 min
and the reaction mixture was allowed to stir at room temperature overnight. The solid was
filtered off and washed with toluene. The organic fraction was evaporated and the residue
obtained was dissolved in xylene (12 ml) and refluxed for 2 hours. The solvent was evaporated
and the residue was purified by column chromatography (50 g Silicagel, dichloromethane) to
yield 387 mg (69%) of a light yellow solid. MS (ISP): 283.1 ([M+H]+
).
c) 1-(4-(Difluoromethoxy)phenyl)-1H-pyrazolecarboxylic acid
To a solution of ethyl 1-(4-(difluoromethoxy)phenyl)-1H-pyrazolecarboxylate (350 mg, 1.24
mmol) in a mixture of THF (3.1 ml), methanol (1.6 ml), Water (1.6 ml) lithium hydroxide
hydrate (89 mg, 3.72 mmol) was added. The solution was heated to 80°C for 2 h. Most of the
organic solvent was removed under reduced pressure. Sodium bicarbonate solution and ethyl
acetate were added and the organic layer was separated. The aqueous layer was made acid by
addition of 25% aqueous hydrochloric acid and the mixture was extracted 2 times with ethyl
acetate. The organic layers were combined, dried (MgSO4) and evaporated. The product was
dried in vacuo and was directly used for the next step.
d) (S)-tert-Butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate
(S)-tert-butyl 2-(4-aminophenyl)morpholinecarboxylate (110 mg, 0.39 mmol), 1-(4-
(difluoromethoxy)phenyl)-1H-pyrazolecarboxylic acid (100 mg, 0.39 mmol), HBTU (167 mg,
0.44 mmol) and N-methylmorpholine (119 mg, 130 µl, 1.18 mmol) were combined with DMF (2
ml) to give a light yellow solution. The reaction mixture was stirred at 50 ° C for 17 hours.
The reaction mixture was poured into 25 ml of water and extracted with ethyl acetate twice. The
combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo.
The crude material was purified by flash chromatography (20 g Silicagel, 30 to 50 % ethyl
acetate in heptane) to yield an off-white solid (130 mg, 64%). MS (ISP): 459.4 (100%, [MtBu+H]+
), 515.4 (5%, [M+H]+
).
e) (S)(4-(Difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
(S)-tert-Butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (130 mg, 0.25 mmol) was dissolved in dioxane
(0.6 ml) and a solution of HCl in dioxane (4M, 0.12 ml, 3.8 mmol) was added. The reaction
mixture was stirred overnight at 60°C. After cooling ether was added, the solid was filtered off,
washed with ether and dried in vacuo to afford (S)(4-(difluoromethoxy)phenyl)-N-(4-
(morpholinyl)phenyl)-1H-pyrazolecarboxamide hydrochloride (90 mg, 79%) as an offwhite solid. MS (ISP): 415.4 ([M+H]+
).
Example 46
(R)(4-(Difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazole
carboxamide hydrochloride
N
H
N
H
O O
N
N
O
F
F
ClH
The title compound was obtained in analogy to example 45 using (R)-tert-butyl 2-(4-
aminophenyl)morpholinecarboxylate instead of (S)-tert-butyl 2-(4-aminophenyl)morpholine4-carboxylate in step c). Off-white solid. MS (ISP): 415.4 ([M+H]+
).
Example 47
(S)-N-(4-(Morpholinyl)phenyl)(5-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide hydrochloride
N
H
N
H
O O
N
N
N
N
F
F
F
ClH
a) (S)-tert-Butyl 2-(4-(1H-pyrazolecarboxamido)phenyl)morpholinecarboxylate
1H-Pyrazolecarboxylic acid (560 mg, 5 mmol) was dissolved in methanol (62 ml) and (S)-
tert-butyl 2-(4-aminophenyl)morpholinecarboxylate (1.39 g, 5 mmol) was added. The solution
was cooled to 0 ° C and 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride
(1.8 g, 6.5 mmol) dissolved in 5 ml methanol was added drop-wise to the reaction mixture in 1
hour. The reaction mixture was stirred at 0 ° C for two hours then overnight at room temperature.
The solvent was evaporated, the residue was dissolved in dichloromethane and adsorbed on
silicagel.
The material was purified by flash chromatography (silica gel, 20 g, 30% to 50% EtOAc in
heptane) to yield a white solid (1.61 g; 86%) which was used for the next step.
b) (S)-tert-Butyl 2-(4-(1-(5-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate
(S)-tert-Butyl 2-(4-(1H-pyrazolecarboxamido)phenyl)morpholinecarboxylate (33 mg,
0.089 mmol) and 2-chloro(trifluoromethyl)pyrimidine (16.2 mg, 0.089 mmol) were dissolved
in DMSO (0.7 ml) and potassium carbonate (24.5 mg, 0.177 mmol) was added. The reaction
mixture was placed on a Büchi shaker for 20 hours at 120 ° C. After cooling the mixture, water
was added followed by extraction with ethyl acetate twice. The combined organic layers were
dried over MgSO4 and evaporated. The crude material was purified by flash chromatography
(silica gel, 5 g, 25% to 50% EtOAc in heptane) to yield an off-white solid (11 mg, 24%). MS
(ISP): 463.1 (100%, [M-tBu+H]+
), 519.3 (10%, [M+H]+
).
c) (S)-N-(4-(Morpholinyl)phenyl)(4-(trifluoromethoxy)phenyl)-1H-pyrazole
carboxamide hydrochloride
(S)-tert-Butyl 2-(4-(1-(5-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamido)phenyl)morpholinecarboxylate (11 mg, 21.2 µmol) was dissolved in dioxane
(80 µL) and a solution of HCl in dioxane (79.6 µL, 318 µmol) was added and the reaction
mixture was stirred at 60° C for 2 hours. After cooling, diethylether was added and the solid was
filtered and washed with diethylether to afford (S)-N-(4-(morpholinyl)phenyl)(4-
(trifluoromethoxy)phenyl)-1H-pyrazolecarboxamide hydrochloride (7 mg, 70%) as an offwhite solid. MS (ISP): 419.3 ([M+H]+
).
Example 48
(S)(6-Chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
H
O O
N
N
N
N
Cl
ClH
The title compound was obtained in analogy to example 47 using 2,6-dichloropyrazine instead of
2-chloro(trifluoromethyl)pyrimidine in step b). Yellow solid. MS (ISP): 385.3
([{35Cl}M+H]+
), 387.3 ([{37Cl}M+H]+
). ([M+H]+
).
Example 49
(S)(3-Chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
H
O O
N
N
N
N
Cl
ClH
a) (S)-tert-Butyl 2-(4-(1-(3-chloropyrazinyl)-1H-pyrazolecarboxamido)phenyl)morpholine4-carboxylate
(S)-tert-Butyl 2-(4-(1H-pyrazolecarboxamido)phenyl)morpholinecarboxylate (90 mg, 0.24
mmol) and 2,3-dichloropyrazine (43 mg, 0.29 mmol) were dissolved in dimethylacetamide (2 ml)
and potassium carbonate (67 mg, 0.48 mmol) was added. The reaction mixture was placed on a
Büchi shaker for 16 hours at 80 ° C. To complete the reaction an additional amount of 2,3-
dichloropyrazine (10 mg) was added and heating was continued for another 2 h at 120°C. After
cooling the mixture, water was added followed by extraction with ethyl acetate twice. The
combined organic layers was dried over MgSO4 and evaporated. The crude material was
purified by flash chromatography (silica gel, 10 g, 25% to 50% EtOAc in heptane) to yield an
off-white gum (48 mg, 42%). MS (ISP): 429.3 (100%, [M-tBu+H]+
), 485.4 (10%, [M+H]+
).
b) (S)(3-Chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
(S)-tert-Butyl 2-(4-(1-(3-chloropyrazinyl)-1H-pyrazolecarboxamido)phenyl)morpholine
carboxylate (44 mg, 90.7 µmol) was dissolved in dioxane (0.35 ml) and a solution of HCl in
dioxane (340 µl, 1.36 mmol) was added and the reaction mixture was stirred at 60° C for 90 min.
The solvent was evaporated and the residue was recrystallized from a mixture of ethyl acetate
and ethanol to yield a light yellow solid (27 mg, 70%). MS (ISP): 385.2 ([{35Cl}M+H]+
), 387.2
([{37Cl}M+H]+
). ([M+H]+
).
Example 50
(S)(5-Chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
H
O O
N
N
N
N
Cl
ClH
The title compound was obtained in analogy to example 49 using 2,5-dichloropyrazine instead of
2,3-dichloropyrazine in step a). Off-white solid. MS (ISP): 385.2 ([{35Cl}M+H]+
), 387.2
([{37Cl}M+H]+
). ([M+H]+
).
Example 51
(S)-N-(4-(Morpholinyl)phenyl)(6-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide hydrochloride
N
H
N
H
O O
N
N
N
N
F
F
F
ClH
The title compound was obtained in analogy to example 49 using 4-chloro
(trifluoromethyl)pyrimidine instead of 2,3-dichloropyrazine in step a). White solid. MS (ISP):
419.2 ([M+H]+
).
Example 52
(S)-N-(4-(Morpholinyl)phenyl)(6-(trifluoromethyl)pyrazinyl)-1H-pyrazole
carboxamide hydrochloride
N
H
N
H
O O
N
N
N
N
F
F
F
ClH
The title compound was obtained in analogy to example 49 using 2-iodo
(trifluoromethyl)pyrazine instead of 2,3-dichloropyrazine in step a). Light yellow solid. MS
(ISP): 419.2 ([M+H]+
).
Example 53
(S)(5-Cyanopyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide
hydrochloride
N
H
N
H
O O
N
N
N
N
N
ClH
The title compound was obtained in analogy to example 49 using 5-bromopyrazine
carbonitrile instead of 2,3-dichloropyrazine in step a). Light yellow solid. MS (ISP): 376.3
([M+H]+
).
Example 54
(S)-N-(4-(Morpholinyl)phenyl)(2-(trifluoromethyl)pyrimidinyl)-1H-pyrazole
carboxamide hydrochloride
N
H
N
H
O O
N
N
N
N
F
F
F
ClH
The title compound was obtained in analogy to example 49 using 4-chloro
(trifluoromethyl)pyrimidine instead of 2,3-dichloropyrazine in step a). Light green solid. MS
(ISP): 419.2 ([M+H]+
).
The compounds of formula I and their pharmaceutically usable addition salts
possess valuable pharmacological properties. Specifically, it has been found that the
compounds of the present invention have a good affinity to the trace amine associated
receptors (TAARs), especially TAAR1.
The compounds were investigated in accordance with the test given hereinafter.
Materials and Methods
Construction of TAAR expression plasmids and stably transfected cell lines
For the construction of expression plasmids the coding sequences of human, rat and mouse
TAAR 1 were amplified from genomic DNA essentially as described by Lindemann et al. [14].
The Expand High Fidelity PCR System (Roche Diagnostics) was used with 1.5 mM Mg2+ and
purified PCR products were cloned into pCR2.1-TOPO cloning vector (Invitrogen) following the
instructions of the manufacturer. PCR products were subcloned into the pIRESneo2 vector (BD
Clontech, Palo Alto, California), and expression vectors were sequence verified before
introduction in cell lines.
HEK293 cells (ATCC # CRL-1573) were cultured essentially as described by Lindemann et al.
(2005). For the generation of stably transfected cell lines HEK293 cells were transfected with the
pIRESneo2 expression plasmids containing the TAAR coding sequences (described above) with
Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer, and 24 hrs
post transfection the culture medium was supplemented with 1 mg/ml G418 (Sigma, Buchs,
Switzerland). After a culture period of about 10 d clones were isolated, expanded and tested for
responsiveness to trace amines (all compounds purchased from Sigma) with the cAMP Biotrak
Enzyme immunoassay (EIA) System (Amersham) following the non-acetylation EIA procedure
provided by the manufacturer. Monoclonal cell lines which displayed a stable EC50 for a culture
period of 15 passages were used for all subsequent studies.
Radioligand binding assay on rat TAAR1
Membrane Preparation and Radioligand Binding.
HEK-293 cells stably expressing rat TAAR1 were maintained at 37 °C and 5% CO2 in DMEM
high glucose medium, containing fetal calf serum (10%, heat inactivated for 30 min at 56 °C),
penicillin/streptomycin (1%), and 375 µg/ml geneticin (Gibco). Cells were released from culture
flasks using trypsin/ EDTA, harvested, washed twice with ice-cold PBS (without Ca2+ and Mg2+),
pelleted at 1’000 rpm for 5 min at 4 °C, frozen and stored at -80 °C. Frozen pellets were
suspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA and homogenized
with a Polytron (PT 6000, Kinematica) at 14’000 rpm for 20 s. The homogenate was centrifuged
at 48’000 x g for 30 min at 4 °C. Subsequently, the supernatant was removed and discarded, and
the pellet resuspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) containing 0.1 mM EDTA
using the Polytron (20 s at 14’000 rpm). This procedure was repeated and the final pellet
resuspended in HEPES-NaOH containing 0.1 mM EDTA and homogenized using the Polytron.
Typically, aliquots of 2 ml membrane portions were stored at -80 °C. With each new membrane
batch the dissociation constant (Kd) was determined via a saturation curve. The TAAR1
radioligand 3
[H]-(S)[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazolylamine (described
in WO 2008/098857) was used at a concentration equal to the calculated Kd value, that was
usually around 2.3 nM, resulting in the binding of approximately 0.2% of the radioligand and a
specific binding representing approximately 85% of the total binding. Nonspecific binding was
defined as the amount of 3
[H]-(S)[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol
ylamine bound in the presence of 10 µM unlabeled ligand. All compounds were tested at a broad
range of concentrations (10 pM to 10 µM) in duplicates. The test compounds (20X µl/well) were
transferred into a 96 deep well plate (TreffLab), and 180 µl of HEPES-NaOH (20 mM, pH 7.4)
containing MgCl2 (10 mM) and CaCl2 (2 mM) (binding buffer), 300 µl of the radioligand 3
[H]-
(S)[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazolylamine at a concentration of 3.3 x
Kd in nM and 500 µl of the membranes (resuspended at 50 µg protein per ml) added. The 96
deep well plates were incubated for 1 hr at 4 °C. Incubations were terminated by rapid filtration
through Unifilter-96 plates (Packard Instrument Company) and glass filters GF/C (Perkin Elmer)
presoaked for 1 hr in polyethylenimine (0.3%) and washed 3 times with 1 ml of cold binding
buffer. After addition of 45 µl of Microscint 40 (PerkinElmer) the Unifilter-96 plate was sealed
and after 1 hr the ratioactivity counted using a TopCount Microplate Scintillation Counter
(Packard Instrument Company).
Radioligand binding assay on mouse TAAR1
Membrane Preparation and Radioligand Binding.
HEK-293 cells stably expressing mouse TAAR1 were maintained at 37 °C and 5% CO2 in
DMEM high glucose medium, containing fetal calf serum (10%, heat inactivated for 30 min at
56 °C), penicillin/streptomycin (1%), and 375 µg/ml geneticin (Gibco). Cells were released from
culture flasks using trypsin/ EDTA, harvested, washed twice with ice-cold PBS (without Ca2+ 30
and Mg2+), pelleted at 1’000 rpm for 5 min at 4 °C, frozen and stored at -80 °C. Frozen pellets
were suspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA and
homogenized with a Polytron (PT 6000, Kinematica) at 14’000 rpm for 20 s. The homogenate
was centrifuged at 48’000 x g for 30 min at 4 °C. Subsequently, the supernatant was removed
and discarded, and the pellet resuspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) containing
0.1 mM EDTA using the Polytron (20 s at 14’000 rpm). This procedure was repeated and the
final pellet resuspended in HEPES-NaOH containing 0.1 mM EDTA and homogenized using the
Polytron. Typically, aliquots of 2 ml membrane portions were stored at -80 °C. With each new
membrane batch the dissociation constant (Kd) was determined via a saturation curve. The
TAAR1 radioligand 3
[H]-(S)[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazolylamine
(described in WO 2008/098857) was used at a concentration equal to the calculated Kd value,
that was usually around 0.7 nM, resulting in the binding of approximately 0.5% of the
radioligand and a specific binding representing approximately 70% of the total binding.
Nonspecific binding was defined as the amount of 3
[H]-(S)[(ethyl-phenyl-amino)-methyl]-
4,5-dihydro-oxazolylamine bound in the presence of 10 µM unlabeled ligand. All compounds
were tested at a broad range of concentrations (10 pM to 10 µM) in duplicates. The test
compounds (20X µl/well) were transferred into a 96 deep well plate (TreffLab), and 180 µl of
HEPES-NaOH (20 mM, pH 7.4) containing MgCl2 (10 mM) and CaCl2 (2 mM) (binding buffer),
300 µl of the radioligand 3
[H]-(S)[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol
ylamine at a concentration of 3.3 x Kd in nM and 500 µl of the membranes (resuspended at 60
µg protein per ml) added. The 96 deep well plates were incubated for 1 hr at 4 °C. Incubations
were terminated by rapid filtration through Unifilter-96 plates (Packard Instrument Company)
and glass filters GF/C (Perkin Elmer) presoaked for 1 hr in polyethylenimine (0.3%) and washed
3 times with 1 ml of cold binding buffer. After addition of 45 µl of Microscint 40 (PerkinElmer)
the Unifilter-96 plate was sealed and after 1 hr the ratioactivity counted using a TopCount
Microplate Scintillation Counter (Packard Instrument Company).
The compounds show a Ki value (µM) in mouse or rat on TAAR1 in the range of <0.1
µM as shown in the table below.
Example Ki (µM)
mouse/rat
Example Ki(µM)
mouse/rat
Example Ki (µM)
mouse/rat
1 0.0007/
0.0043
19 0.0079/
0.0028
37 0.0017/
0.0027
2 0.0003/
0.0004
0.0022 /
0.0074
38 0.0021/
0.0042
3 0.0008/
0.0027
21 0.0053/
0.0055
39 0.0014/
0.003
4 0.001/
0.0022
22 0.0023 /
0.0022
40 0.0005/
0.0013
0.0072/
0.0045
23 0.0064/
0.0088
41 0.0025/
0.0016
6 0.0016/
0.008
24 0.0067/
0.0142
42 0.001/
0.0021
7 0.0012/
0.0049
0.0051/
0.0078
43 0.0016/
0.011
8 0.0009/
0.0073
26 0.0734/
0.0316
44 0.0663/
0.0262
9 0.0014/
0.014
27 0.0021/
0.0135
45 0.0018/
0.0014
0.0005/
0.0026
28 0.0043/
0.0129
46 0.004/
0.0006
11 0.0026/
0.0127
29 0.0011/
0.0024
47 0.0198/
0.0196
12 0.0005/
0.0004
0.1428/
1.3212
48 0.0086/
0.0118
13 0.0008/
0.001
31 0.0013/
0.0024
49 0.0142/
0.139
14 0.0017 /
0.0028
32 0.0007/
0.0011
50 0.0027/
0.0091
0.0006/
0.0004
33 0.0028/
0.0016
51 0.0142/
0.0071
16 0.0013/
0.0014
34 0.0037/
0.0092
52 0.0084/
0.0074
17 0.0016 /
0.0024
0.0022/
0.0006
53 0.011/
0.0298
18 0.0017/
0.0254
36 0.0014/
0.0138
54 0.0065/
0.0088
The compounds of formula IA and IB and the pharmaceutically acceptable salts of the
compounds of formula IA and IB can be used as medicaments, e.g. in the form of pharmaceutical
preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of
tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of
suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula IA and IB can be processed with pharmaceutically inert,
inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn
starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example,
as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers
for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid
polyols and the like. Depending on the nature of the active substance no carriers are however
usually required in the case of soft gelatine capsules. Suitable carriers for the production of
solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semiliquid or liquid polyols and the like.
The pharmaceutical preparations can, moreover, contain preservatives, solubilizers,
stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the
osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other
therapeutically valuable substances.
Medicaments containing a compound of formula IA or IB or a pharmaceutically
acceptable salt thereof and a therapeutically inert carrier are also an aspect of the present
invention, as is a process for their production, which comprises bringing one or more compounds
of formula IA or IB and/or pharmaceutically acceptable acid addition salts and, if desired, one or
more other therapeutically valuable substances into a galenical administration form together with
one or more therapeutically inert carriers.
The most preferred indications in accordance with the present invention are those which
include disorders of the central nervous system, for example the treatment or prevention of
depression, psychosis, Parkinson’s disease, anxiety and attention deficit hyperactivity disorder
(ADHD) and diabetes.
The dosage can vary within wide limits and will, of course, have to be adjusted to the
individual requirements in each particular case. In the case of oral administration the dosage for
adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula
I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage
may be administered as single dose or in divided doses and, in addition, the upper limit can also
be exceeded when this is found to be indicated.
Tablet Formulation (Wet Granulation)
Item Ingredients mg/tablet
5 mg 25 mg 100 mg 500
mg
1. Compound of formula I 5 25 100 500
2. Lactose Anhydrous DTG 125 105 30 150
3. Sta-Rx 1500 6 6 6 30
4. Microcrystalline Cellulose 30 30 30 150
. Magnesium Stearate 1 1 1 1
Total 167 167 167 831
Manufacturing Procedure
1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.
Capsule Formulation
Item Ingredients mg/capsule
5 mg 25 mg 100 mg 500
mg
1. Compound of formula I 5 25 100 500
2. Hydrous Lactose 159 123 148 ---
3. Corn Starch 25 35 40 70
4. Talc 10 15 10 25
. Magnesium Stearate 1 2 2 5
Total 200 200 300 600
Manufacturing Procedure
1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.
Claims (18)
1. A compound of formula R 1 N N N H O NH Z R 2 R 3 IA or R 1 N N N H O NH Z R 2 R 4 IB 5 wherein R 1 is hydrogen or phenyl, optionally substituted by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R 2 is hydrogen or lower alkyl; R 3 is hydrogen or lower alkyl or is 10 phenyl substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is 15 pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; R 4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or –O-; or a pharmaceutically suitable acid addition salt thereof. 20
2. A compound of formula IA-1according to claim 1, (R)n N N N H O NH R 2 R 3 Z IA-1 wherein R is hydrogen, halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R 2 is hydrogen or lower alkyl; R
3 5 is hydrogen or lower alkyl; Z is a bond, -CH2- or –O-; n is 1 or 2; if n = 2, each R may be defined independently of the other; or a pharmaceutically suitable acid addition salt thereof. 10 3. A compound of formula IA-1 according to any one of claims 1 or 2, wherein the compounds are: (S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide (S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide (S)(3-cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide 15 (S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(5-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or (S)(3-(difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole carboxamide. 20
4. A compound of formula IB-1 according to claim 1 (R)n N N N H O NH R 2 R 4 Z IB-1 wherein R is hydrogen, halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R 2 is hydrogen or lower alkyl; R 4 is hydrogen or lower alkyl; 5 Z is a bond, -CH2- or –O-; n is 1 or 2; if n = 2, each R may be defined independently of the other; or a pharmaceutically suitable acid addition salt thereof.
5. A compound of formula IB-1 according to any one of claims 1 or 4, wherein the compounds 10 are (S)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide 15 (S)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide (S)(4-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(2-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(2-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide 20 (S)(3,4-dimethoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)(2-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(4-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)(3-chlorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide 25 (R)(3-methoxyphenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-chlorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)methyl-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide (S)(4-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(4-fluorophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide 30 (S)(3-methoxyphenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-cyanophenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(4-cyanophenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide (R)(3-cyanophenyl)-N-(4-(piperidinyl)phenyl)-1H-pyrazolecarboxamide (rac) 3-(3-cyanophenyl)-N-(4-(pyrrolidinyl)phenyl)-1H-pyrazolecarboxamide 5 (S)(3-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-(difluoromethoxy)phenyl)ethyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole carboxamide (S)(3-cyanofluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or (S)(3-(difluoromethoxy)phenyl)methyl-N-(4-(morpholinyl)phenyl)-1H-pyrazole 10 carboxamide.
6. A compound of formula IA-2 according to claim 1, R 1 N N N H O NH R 2 R 3 Z IA-2 R 1 is hydrogen; R 2 15 is hydrogen or lower alkyl; R 3 phenyl substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is 20 pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; Z is a bond, -CH2- or –O-; or a pharmaceutically suitable acid addition salt thereof.
7. A compound of formula IA-2 according to any one of claims 1 or 6, wherein the compounds 25 are (S)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)(4-fluorophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(5-chloropyridinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole carboxamide (S)(4-cyanophenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyridinyl)-1H-pyrazole 5 carboxamide (S)(4-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (R)(4-(difluoromethoxy)phenyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)-N-(4-(morpholinyl)phenyl)(5-(trifluoromethyl)pyrimidinyl)-1H-pyrazole carboxamide 10 (S)(6-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(3-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)(5-chloropyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide (S)-N-(4-(morpholinyl)phenyl)(6-(trifluoromethyl)pyrimidinyl)-1H-pyrazole carboxamide 15 (S)-N-(4-(morpholinyl)phenyl)(6-(trifluoromethyl)pyrazinyl)-1H-pyrazole carboxamide (S)(5-cyanopyrazinyl)-N-(4-(morpholinyl)phenyl)-1H-pyrazolecarboxamide or (S)-N-(4-(morpholinyl)phenyl)(2-(trifluoromethyl)pyrimidinyl)-1H-pyrazole carboxamide. 20
8. A compound of formula IB-2 according to claim 1, N N N H O NH R 2 R 4 Z R 1 IB-2 wherein R 1 is hydrogen; R 2 25 is hydrogen or lower alkyl; R 4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or –O-; or a pharmaceutically suitable acid addition salt thereof.
9. A compound of any one of claims 1 or 8, wherein the compound is (S)-N-(4-(morpholinyl)phenyl)phenyl-1H-pyrazolecarboxamide. 5 10. A process for the manufacture of a compound of formula IA or IB as defined in any one of claims 1 – 9, which process comprises a) cleaving off the N-protecting group from compounds of formula R 1 N N N H O N Z R 2 R 3 PG 4-A or R 1 N N N H O N Z R 2 R 4 PG 4-B
10 to a compound of formula R 1 N N N H O NH Z R 2 R 3 IA or R 1 N N N H O NH Z R 2 R 4 IB wherein PG is a N-protecting group selected from –C(O)O-tert-butyl and the other definitions are as described in claim 1, and, if desired, converting the compounds obtained into pharmaceutically acceptable acid 15 addition salts.
11. A compound according to any one of claims 1 –9, when manufactured by a process according to claim 10. 20
12. A pharmaceutical composition comprising a compound according to any one of claims 1 –9 and a pharmaceutical acceptable carrier and/or adjuvant.
13. A pharmaceutical composition comprising a compound according to any one of claims 1 –9 and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress5 related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson’s disease, neurodegenerative disorders, Alzheimer’s disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular 10 disorders.
14. Compounds according to any one of claims 1 – 9 for use as therapeutic active substances.
15. Compounds according to any one of claims 1 –9 for use as therapeutic active substances in 15 the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson’s disease, neurodegenerative disorders, Alzheimer’s disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, 20 disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
16. The use of a compound according to any one of claims 1 –9 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, 25 bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson’s disease, neurodegenerative disorders, Alzheimer’s disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of 30 body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
17. A process according to claim 10 substantially as herein described with reference to any example thereof.
18. A pharmaceutical composition according to claim 12 substantially as herein described with 5 reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11169217 | 2011-06-09 | ||
EP11169217.4 | 2011-06-09 | ||
PCT/EP2012/060627 WO2012168260A1 (en) | 2011-06-09 | 2012-06-06 | Pyrazole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617350A NZ617350A (en) | 2016-01-29 |
NZ617350B2 true NZ617350B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012266457B2 (en) | Pyrazole derivatives | |
AU2012266462B2 (en) | Substituted benzamide derivatives | |
US9416127B2 (en) | Triazole carboxamides and uses thereof | |
CA2856204A1 (en) | Heterocyclic derivatives as trace amine associated receptors (taars) | |
CA2882821C (en) | Pyrazole carboxamide derivatives and uses thereof as taar modulators | |
CA2889627A1 (en) | Pyrazine derivatives | |
NZ617350B2 (en) | Pyrazole derivatives and their use for the treatment of diseases relating to TAARs, such as depression, psychosis, Parkinson's disease, ADHD and diabetes | |
NZ616820B2 (en) | Substituted benzamide derivatives |